LobbyingUltragenyx Pharmaceutical lobbying by quarter
Ultragenyx Pharmaceutical RARE's latest lobbying report covers Q2 2026, at $680K. The four quarters Q4 2025–Q3 2026 total $1.5M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Budget/Appropriations.
Ultragenyx PharmaceuticalRARE
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.5M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $50K | 1 |
| Q1 2023 | $50K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $40K | 1 |
| Q4 2023 | $40K | 1 |
| Q1 2024 | $220K | 1 |
| Q2 2024 | $30K | 1 |
| Q3 2024 | $130K | 2 |
| Q4 2024 | $160K | 2 |
| Q1 2025 | $390K | 2 |
| Q2 2025 | $238K | 3 |
| Q3 2025 | $238K | 3 |
| Q4 2025 | $228K | 3 |
| Q1 2026 | $550K | 6 |
| Q2 2026 | $680K | 5 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$1.4M · 30 reports
- Budget and appropriations$733.3K · 13 reports
- Medicare and Medicaid$623.3K · 9 reports
- Medical research and clinical labs$173.3K · 4 reports
- Government issues$33.3K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES29 reports
- SENATE28 reports
- Health & Human Services, Dept of (HHS)11 reports
- Office of Management & Budget (OMB)4 reports
- Food & Drug Administration (FDA)2 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- Executive Office of the President (EOP)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseUltragenyx Pharmaceutical | $2M | 10 quarters |
| Mehlman Consulting | $460K | 8 quarters |
| Forbes-Tate | $280K | 7 quarters |
| Miller Strategies | $140K | 2 quarters |
| Aviva Strategies | $114K | 4 quarters |
| Alpine Group Partners | $100K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ERIN MENDELSOHN | LD, Rep. Anna Eshoo; Congressional Liaison - FDA | Q2 2026 |
| KEENAN AUSTIN REED | Chief of Staff, Rep. Donald McEachin; Deputy Chief of Staff, Rep. Frederica S.Wilson | Q2 2026 |
| SHAYNE WOODS | Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep. Gus Bilirakis | Q2 2026 |
| ASHLEY GUNN | Special Asst to the President, Senior Director, White House Office of Cabinet Affairs. | Q1 2026 |
| NATALIE MCINTYRE | Special Assistant to the President, Office of Legislative Affairs; Sen. Bill Hagerty Legislative Director; OMB Deputy Associate Director, Legislative Affairs; ONDCP Senior Policy Advisor and White House Liaison; Sen. McConnell Legislative Assistant | Q1 2026 |
| EARL SCOTT FLOOD | Dep. CoS, LD (Rep. Robin Kelly); Health Pol Adv, Csl (Rep. Terri Sewell); Csl (Rep. Cedric Richmond); Pol Aide (Sen. Claire McCaskill) | Q4 2025 |
| JOSEPH EDWARD BROWN iii | Sr Prof Staff (EPW Comm Maj/Sen. Moore Capito); Prof Staff (EPW Comm Min/Ranking Mem Sen. Moore Capito); Leg Asst (Sen. Boozman); Maj Leg Asst (EPW Comm Maj/Sen. Jim Inhofe); Maj Research Asst (EPW Comm Maj/Sen. Jim Inhofe); Intern (Rep. Jim Renacci) | Q3 2025 |
| JON ADAME | CoS, LD, GC (Sen. Blackburn); Counsel (Rep. Blackburn); Policy Coordinator (House E&C); Intern (Sen. Domenici) | Q2 2025 |
| ANNIE WOLF | Dep Floor Dir (Maj Leader Scalise); CoS (Chief Dep Min Whip Ferguson); Dep Floor Dir (Min Whip Scalise); Prof Staff (House Rules/Sessions); Floor Asst (Speakers Ryan & Boehner); Staff Asst (Speaker Boehner); Intern (Rep. Sullivan) | Q3 2024 |
| NAVEEN PARMAR | Chief Counsel (Sen. Hickenlooper); General Counsel (House Comm on Sm Bus/Velazquez); Tax Counsel, (House Comm on Sm Bus/Velazquez); Economic Policy Counsel (Sen. Amy Klobuchar); Ways and Means Counsel (Rep. Lloyd Doggett) | Q3 2024 |
| ARTHUR DENNIS SIDNEY | LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020) | Q2 2023 |
| CYNTHIA BROWN | Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002) | Q1 2023 |
| ELIZABETH GREER | Chief of Staff, Rep. Allen Boyd (2001-2009) | Q1 2023 |
| KRISTINA DUNKLIN | Legislative Director, Rep. Susan Brooks (2018-2019); Legislative Director, Rep. David Valadao (2015-2018); Legislative Assistant, Rep. David Valadao (2014-2015) | Q1 2023 |
| MICHAEL ALEXANDER WILLIAMS | Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Brian Jones (2019); Legislative Correspondent, Sen. Brian Jones (2018-2019) | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Forbes-Tate | $30K |
| 07/20for Q2 | In-house | $390K |
| 07/20for Q1 | Alpine Group Partners | $40K |
| 07/20for Q2 | Alpine Group Partners | $60K |
| 07/20for Q2 | Miller Strategies | $140K |
| 07/20for Q2 | Mehlman Consulting | $60K |
| 07/13for Q1 | Alpine Group Partners | Under $5,000 |
| 04/20for Q1 | Forbes-Tate | $10K |
| 04/20for Q1 | Miller Strategies | Under $5,000 |
| 04/20for Q1 | Aviva Strategies | Under $5,000 |
| 04/17for Q1 | Mehlman Consulting | $60K |
| 04/17for Q1 | In-house | $440K |
| 04/17for Q1 | Forbes-Tate | Under $5,000 |
| 03/30for Q1 | Miller Strategies | Under $5,000 |
| 01/16for Q4 2025 | In-house | $130K |
| 01/16for Q4 2025 | Mehlman Consulting | $60K |
| 01/15for Q4 2025 | Aviva Strategies | $38K |
| 25/10/17for Q3 2025 | In-house | $140K |
| 25/10/17for Q3 2025 | Mehlman Consulting | $60K |
| 25/10/15for Q3 2025 | Aviva Strategies | $38K |